Moleculin Biotech, Inc., (Nasdaq: MBRX) shares are trade -2.84% to $4.78. Based on the relationship between its 200-day and 20-day major moving averages, Moleculin Biotech Inc. (MBRX) has been in rally mode. MBRX shares have risen 4.72% in the past 30 days. Stocks have declined -7.98% over the trailing 12 months, outperforming the market by 262.16%. Its performance trailed competitor brands by 30.32 percent.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Moleculin Biotech, Inc. develops vaccines to treat non-communicable diseases such as viral hepatitis and HIV.
Meanwhile, in the global biopharmaceutical industry, Catalyst offers highly customizable clinical research solutions, including Catalyst Flex and Catalyst Oncology. Through offices in the US and EU and over 500 staff, the company provides multitherapeutic global sourcing and functional services through Catalyst Flex, and a comprehensive oncology CRO service through Catalyst Oncology.
What just happened
Moleculin Biotech, Inc., (Nasdaq: MBRX) announced today that it has entered into a research agreement with Catalyst Clinical Research, Inc., a contract research organization, to manage its US clinical trial to study Annamycin’s ability to treat sarcomas that have spread to the lungs.
Approximately 130,000 incident sarcoma cases are reported every year through soft tissue sarcomas. The removal of many sarcomas can be accomplished by surgery, but as many as 20% to 50% will end up metastasizing to the lungs, in which case treatment becomes challenging.
Anthracycline doxorubicin, or Adriamycin, is the primary chemotherapy regimen used if tumors have spread to the lungs if surgical removal is not possible. Although 10 to 30% of patients with sarcoma lung metastases initially respond to doxorubicin, many will relapse, leaving them with no other option for treatment. Several anthracycline drugs, including doxorubicin, carry inherent cardiotoxicity, which further limits treatment options.
Approximately 34 times the concentration of doxorubicin has been found in the lungs of animals treated with annamycin. Moreover, Annamycin has also showed an absence of cardiotoxicity during human clinical trials focusing on acute myeloid leukemia, therefore it will not have to undergo the same dose restrictions imposed on doxorubicin.
Experts agree that drug development is at its peak in our lifetimes. Science is providing new insights into the prevention and treatment of diseases previously unknown. If approved by authorities, the pharmaceutical industry is likely to provide investors with huge returns.